Nuvectis Pharma (NVCT) News Today $8.68 -1.13 (-11.52%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$9.07 +0.40 (+4.55%) As of 03/25/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Nuvectis Pharma, Inc. (NASDAQ:NVCT) Short Interest UpdateNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 1,340,000 shares, a decline of 14.1% from the February 13th total of 1,560,000 shares. Based on an average daily volume of 107,000 shares, the short-interest ratio is currently 12.5 days. Currently, 11.1% of the shares of the company are sold short.March 20, 2025 | marketbeat.comNuvectis Pharma (NASDAQ:NVCT) Coverage Initiated by Analysts at LaidlawMarch 19, 2025 | americanbankingnews.comLaidlaw Begins Coverage on Nuvectis Pharma (NASDAQ:NVCT)Laidlaw initiated coverage on shares of Nuvectis Pharma in a research report on Monday. They set a "buy" rating and a $19.00 price target for the company.March 18, 2025 | marketbeat.comLaidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy RecommendationMarch 18, 2025 | msn.comNuvectis Pharma initiated with a Buy at LaidlawMarch 17, 2025 | markets.businessinsider.comNuvectis Pharma (NASDAQ:NVCT) and Sunshine Biopharma (NASDAQ:SBFM) Head to Head AnalysisMarch 16, 2025 | americanbankingnews.comNuvectis Pharma to Participate in the 37th Annual Roth ConferenceMarch 14, 2025 | globenewswire.comNuvectis announces new publication of research study on NXP900, osimertinibMarch 5, 2025 | markets.businessinsider.comAnalysts Set Expectations for Nuvectis Pharma Q1 EarningsNuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Nuvectis Pharma in a note issued to investors on Tuesday, February 25th. HC Wainwright analyst J. Pantginis expects that the company will post earniMarch 1, 2025 | marketbeat.comRoth Capital Forecasts Reduced Earnings for Nuvectis PharmaNuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Equities researchers at Roth Capital lowered their Q1 2025 earnings per share estimates for Nuvectis Pharma in a research report issued on Tuesday, February 25th. Roth Capital analyst J. Aschoff now anticipates that the company will post earningMarch 1, 2025 | marketbeat.comFY2028 EPS Forecast for Nuvectis Pharma Reduced by AnalystNuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Equities research analysts at Roth Capital lowered their FY2028 earnings per share (EPS) estimates for shares of Nuvectis Pharma in a research note issued to investors on Tuesday, February 25th. Roth Capital analyst J. Aschoff now anticipates thFebruary 28, 2025 | marketbeat.comMarket News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital MarketsFebruary 27, 2025 | businesswire.comNuvectis Pharma price target lowered to $11 from $21 at H.C. WainwrightFebruary 25, 2025 | markets.businessinsider.comHC Wainwright Cuts Nuvectis Pharma (NASDAQ:NVCT) Price Target to $11.00HC Wainwright cut their price objective on shares of Nuvectis Pharma from $21.00 to $11.00 and set a "buy" rating on the stock in a report on Tuesday.February 25, 2025 | marketbeat.comNuvectis Pharma (NASDAQ:NVCT) Issues Earnings ResultsNuvectis Pharma (NASDAQ:NVCT - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.08).February 25, 2025 | marketbeat.comNuvectis Pharma reports FY24 EPS ($1.11) vs. ($1.43) last yearFebruary 25, 2025 | markets.businessinsider.comNuvectis Pharma, Inc. Reports 2024 Financial Results and Business HighlightsFebruary 25, 2025 | finance.yahoo.comNuvectis Pharma (NVCT) to Release Earnings on TuesdayNuvectis Pharma (NASDAQ:NVCT) will be releasing earnings before the market opens on Tuesday, March 4.February 25, 2025 | marketbeat.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Marlio Charles Mosseri Buys 240,000 SharesFebruary 12, 2025 | insidertrades.comNuvectis pharma investor acquires $1.2 million in stockFebruary 11, 2025 | msn.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Acquires 240,000 Shares of StockNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) major shareholder Marlio Charles Mosseri bought 240,000 shares of the company's stock in a transaction that occurred on Friday, February 7th. The shares were bought at an average price of $5.00 per share, for a total transaction of $1,200,000.00. Following the acquisition, the insider now directly owns 2,884,121 shares of the company's stock, valued at $14,420,605. This represents a 9.08 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.February 11, 2025 | marketbeat.comNuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment OptionFebruary 7, 2025 | markets.businessinsider.comNuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment OptionFebruary 7, 2025 | globenewswire.comNuvectis Pharma launches public stock offeringFebruary 5, 2025 | msn.comNuvectis Pharma announces common stock offering, no amount givenFebruary 5, 2025 | markets.businessinsider.comNuvectis Pharma 2.7M share Spot Secondary priced at $5.00February 5, 2025 | msn.comNuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offeringFebruary 5, 2025 | msn.comNuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common StockFebruary 5, 2025 | globenewswire.comNuvectis Pharma Announces Proposed Public Offering of Common StockFebruary 4, 2025 | globenewswire.comFavourable Signals For Nuvectis Pharma: Numerous Insiders Acquired StockFebruary 4, 2025 | finance.yahoo.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Holdings Increased by Baldwin Wealth Partners LLC MABaldwin Wealth Partners LLC MA raised its position in shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) by 104.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 355,961 shares of the company'January 27, 2025 | marketbeat.comNuvectis Pharma: Still Flat, Although There May Be A Ground Floor HereJanuary 7, 2025 | seekingalpha.comInsiders hold 63% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recentlyJanuary 4, 2025 | finance.yahoo.comNuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Acquires $20,925.00 in StockDecember 27, 2024 | insidertrades.comNuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Buys $20,925.00 in StockNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur bought 4,500 shares of the company's stock in a transaction on Tuesday, December 24th. The stock was bought at an average cost of $4.65 per share, for a total transaction of $20,925.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,270,924 shares of the company's stock, valued at approximately $15,209,796.60. This represents a 0.14 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.December 26, 2024 | marketbeat.comMarlio Charles Mosseri Purchases 17,000 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) StockDecember 17, 2024 | insidertrades.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Acquires $79,900.00 in StockNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) major shareholder Marlio Charles Mosseri acquired 17,000 shares of the company's stock in a transaction on Friday, December 13th. The shares were purchased at an average cost of $4.70 per share, with a total value of $79,900.00. Following the completion of the purchase, the insider now directly owns 2,612,000 shares of the company's stock, valued at $12,276,400. This trade represents a 0.66 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.December 16, 2024 | marketbeat.comNuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors SymposiumDecember 10, 2024 | markets.businessinsider.comNuvectis Pharma Share Price (NVCT.US)November 19, 2024 | lse.co.ukNuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 20,000 SharesNovember 19, 2024 | insidertrades.comNuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Buys $98,400.00 in StockNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur acquired 20,000 shares of Nuvectis Pharma stock in a transaction on Friday, November 15th. The shares were purchased at an average price of $4.92 per share, for a total transaction of $98,400.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,266,424 shares in the company, valued at $16,070,806.08. This trade represents a 0.62 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.November 18, 2024 | marketbeat.comNuvectis Pharma reports data from Phase 1b study of NXP800November 15, 2024 | finance.yahoo.comNuvectis Pharma Inc trading halted, volatility trading pauseNovember 15, 2024 | markets.businessinsider.comPositive Outlook for Nuvectis Pharma: Promising Clinical and Preclinical Developments Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comNuvectis Pharma Stock Plummets on Updated Data for Ovarian Cancer StudyNovember 14, 2024 | marketwatch.comNuvectis sinks after early-stage data for ovarian cancer therapyNovember 14, 2024 | seekingalpha.comNuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead DrugNovember 14, 2024 | benzinga.comNuvectis Pharma Reports Improved Q3 Financials and Clinical ProgressNovember 7, 2024 | markets.businessinsider.comNuvectis Pharma FY2024 EPS Estimate Boosted by Roth CapitalNuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Stock analysts at Roth Capital increased their FY2024 EPS estimates for Nuvectis Pharma in a research report issued to clients and investors on Tuesday, November 5th. Roth Capital analyst J. Aschoff now expects that the company will earn ($1.00)November 7, 2024 | marketbeat.comRoth Capital Predicts Nuvectis Pharma Q1 EarningsNuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Equities research analysts at Roth Capital issued their Q1 2025 earnings per share (EPS) estimates for Nuvectis Pharma in a research note issued on Tuesday, November 5th. Roth Capital analyst J. Aschoff forecasts that the company will post earniNovember 6, 2024 | marketbeat.com Remove Ads Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address NVCT Media Mentions By Week NVCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NVCT News Sentiment▼0.700.77▲Average Medical News Sentiment NVCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NVCT Articles This Week▼31▲NVCT Articles Average Week Remove Ads Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PAHC News DAWN News ZYME News EOLS News PHVS News AVDL News COGT News OCS News CDMO News QURE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NVCT) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
